Diabetic Kidney Disease Market Size (7MM) was ~USD 7200 million in 2023 and it is expected to grow by 2034

The Diabetic Kidney Disease Market in the 7MM was valued at ~USD 7200 Million in 2023, over the forecast period from 2024 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Diabetic Kidney Disease Market Landscape. By analyzing historical data, current Diabetic Kidney Disease Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Diabetic Kidney Disease Market is increasingly guided by biomarker-driven strategies. Diabetic Kidney Disease (DKD), also known as diabetic nephropathy, is a long-term complication of diabetes in which high blood sugar levels gradually damage the kidneys’ filtering units. Over time, this reduces the kidneys’ ability to remove waste and excess fluid from the body, leading to protein leakage in urine, rising blood pressure, swelling, and ultimately kidney failure if untreated. DKD progresses slowly and often shows no symptoms in early stages, making routine screening in diabetics crucial. Managing blood sugar, blood pressure, and lifestyle factors plays a central role in slowing its progression and protecting kidney function.

DelveInsight’s report, “Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Diabetic Kidney Disease Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Diabetic Kidney Disease Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Diabetic Kidney Disease Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Diabetic Kidney Disease Market Forecast

Some of the key facts of the Diabetic Kidney Disease Market Report

• The leading Diabetic Kidney Disease Companies, such as Daiichi Sankyo, Prokidney, Astrazeneca, Palatin, Chinook Therapeutics, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.

• Promising Diabetic Kidney Disease Therapies such as BAY94-8862, BI 685509, Finerenone (BAY94-8862), Telmisartan capsule 40 mg, PF-00489791, Losartan, Valsartan, MT-3995, and others.

• The Diabetic Kidney Disease Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Diabetic Kidney Disease Pipeline products will significantly revolutionize the Diabetic Kidney Disease Market Dynamics.

Diabetic Kidney Disease Overview

Diabetic Kidney Disease is a serious yet gradual decline in kidney function that develops in people with diabetes due to prolonged high blood sugar damaging the tiny blood vessels responsible for filtering waste. As the kidneys weaken, protein begins to leak into the urine and waste builds up in the blood, often without noticeable symptoms at first. Progression can eventually lead to swelling, rising blood pressure, and the risk of kidney failure. Early detection, tight control of glucose and blood pressure, and kidney-protective treatments are key to slowing this condition and preserving long-term kidney health.

Get a Free sample for the Diabetic Kidney Disease Market Report @ https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market

Key Trends in the Diabetic Kidney Disease Therapeutics Market

• Increasing Adoption of SGLT2 and RAAS-Targeted Therapies

Therapeutic advances continue to emphasize the role of SGLT2 inhibitors and renin–angiotensin–aldosterone system (RAAS) modulators, which demonstrate kidney-protective effects beyond glycemic control. These agents are increasingly becoming standard-of-care in DKD management.

• Expansion of Combination Therapeutic Strategies

Combination regimens involving SGLT2 inhibitors, DPP-4 agents, mineralocorticoid receptor antagonists (MRAs), and ACE/ARB therapies are gaining traction to enhance renal protection and slow disease progression. This strategic layering reflects the shift toward multipronged disease management.

• Growing Clinical Interest in Novel Anti-Inflammatory and Anti-Fibrotic Agents

Inflammation and fibrosis are key pathological drivers in DKD. Emerging drug candidates targeting cytokine pathways, oxidative stress, and extracellular matrix remodeling are gaining clinical attention with the aim of modifying underlying disease mechanisms.

• Focus on Early Diagnosis and Disease Progression Monitoring

Rising clinical emphasis is placed on early-stage detection through biomarker profiling and renal function monitoring. New diagnostic tools and risk stratification models are enabling intervention before irreversible kidney damage occurs.

• Increasing Use of Biomarkers for Precision Therapy

Circulating prognostic and predictive biomarkers, including microalbuminuria, GFR-related markers, and molecular signatures, are being evaluated to guide personalized therapeutic decisions, improve treatment selection, and monitor response.

• Rising Preference for Non-Invasive and Patient-Friendly Therapeutics

Oral therapies, improved dosing schedules, and formulations with fewer systemic effects are gaining favor, supporting treatment adherence among chronic DKD patients.

• Growing Integration of Digital Health and Remote Monitoring Solutions

Telemedicine, wearable renal-monitoring solutions, and mobile health platforms are increasingly adopted for continuous assessment of kidney function, medication adherence, and metabolic control, optimizing outcomes for high-risk patients.

• Increasing Focus on Cardiovascular–Renal Continuum Management

Therapeutics are increasingly evaluated for both renal and cardioprotective benefits due to the high interplay between diabetic kidney disease and cardiovascular morbidity, guiding more holistic treatment development.

Diabetic Kidney Disease Epidemiology Segmentation in the 7MM

The Diabetic Kidney Disease Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Prevalent Cases of Diabetes
• Total Diagnosed Prevalent Cases of Diabetes
• Total Prevalent Cases of Diabetic Kidney Disease
• Age-specific Cases of Diabetic Kidney Disease
• Stage-Specific Cases of Diabetic Kidney Disease

Download the report to understand which factors are driving Diabetic Kidney Disease Epidemiology trends @ Diabetic Kidney Disease Epidemiology Forecast

Recent Development in the Diabetic Kidney Disease Treatment Landscape

• In December 2025, PT. JES Kasih Nusantara Sejahterah initiated a clinical trial to assess whether subcutaneous administration of autologous dendritic cells (DC) and lymphocytes can improve albuminuria and endothelial dysfunction in patients with Type 2 Diabetes Mellitus (T2DM) who have Diabetic Kidney Disease (DKD).
• In November 2025, Bayer launched a Phase 3 clinical study to evaluate the efficacy and safety of finerenone, when added to the standard of care, in slowing the progression of kidney disease among patients with non-diabetic chronic kidney disease.
• In November 2025, Shandong Suncadia Medicine Co., Ltd conducted a 16-week, multicenter, randomized, double-blind, placebo-controlled Phase II trial aimed at determining the safety and efficacy of HRS-7535 in individuals with Type 2 Diabetic Kidney Disease.

Diabetic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Diabetic Kidney Disease drugs recently launched in the Diabetic Kidney Disease market or expected to get launched during the study period. The analysis covers Diabetic Kidney Disease Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Diabetic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Kidney Disease Companies and Therapies

• Bayer: BAY94-8862
• Boehringer Ingelheim: BI685509
• Organon and Co: MK0954
• Pfizer: PF-00489791
• Chong Kun Dang Pharmaceutical: Telmisartan/Losartan
• Tanabe Pharma Corporation: MT-3995

To know more about Diabetic Kidney Disease Companies working in the treatment market, visit @ Diabetic Kidney Disease Clinical Trials and Therapeutic Assessment

Diabetic Kidney Disease Market Drivers

• Rising Global Diabetes Prevalence

The continued surge in diabetes cases worldwide remains the strongest market driver for diabetic kidney disease (DKD). Increasing rates of type 2 diabetes across all age groups directly correlate with a higher risk of kidney complications, boosting the demand for preventive, diagnostic, and therapeutic interventions.

• Growing Focus on Early Diagnosis and Screening Programs

Greater emphasis on early identification of renal impairment in diabetic patients is accelerating market growth. Routine screening for proteinuria, microalbuminuria, and GFR decline is becoming standard clinical practice, leading to earlier disease detection and increased treatment initiation.

• Advancements in Therapeutic Options

Recent progress in treatment approaches, including SGLT2 inhibitors, RAS blockade, anti-inflammatory pathways, and combination therapies, is expanding clinical adoption. These emerging therapies not only slow disease progression but also improve cardiovascular outcomes, positioning DKD management as a priority for clinicians.

• Increasing Awareness of Disease Burden and Outcomes

Rising awareness of the severity and long-term consequences of diabetic kidney disease — including risk of dialysis, cardiovascular complications, and mortality — has led to intensified research focus and stronger clinical intervention strategies, driving market growth.

• Shift Toward Personalized and Multidisciplinary Care

Healthcare systems are increasingly adopting personalized and multidisciplinary strategies integrating diabetologists, nephrologists, and cardiologists. This collaborative approach enhances disease management, improves patient outcomes, and increases the utilization of diagnostics and therapeutics.

Diabetic Kidney Disease Market Barriers

• Delayed Diagnosis and Under-Recognition

Early-stage DKD often remains asymptomatic, leading to missed or delayed diagnosis. Lack of standardized screening practices, limited disease awareness among patients, and inadequate monitoring of renal biomarkers contribute to late intervention, diminishing therapeutic effectiveness.

• Limited Availability of Effective Disease-Modifying Treatments

Despite advancements in diabetes care, treatment options that directly halt or reverse kidney damage remain limited. Most therapies focus on symptom control rather than modifying underlying disease pathways, creating a persistent unmet medical need.

• Heterogeneity in Disease Progression and Patient Response

DKD progression varies widely among patients due to differences in metabolic profile, comorbidities, and genetic predisposition. This variability complicates clinical trial design, endpoint selection, and regulatory approval timelines, ultimately slowing therapeutic innovation.

• High Economic Burden and Access Challenges

Advanced therapies, frequent monitoring, and dialysis/renal care drive substantial economic burden. In many regions, reimbursement restrictions and affordability issues limit patient access to emerging treatments, especially in lower-income healthcare settings.

• Limited Early-Stage Clinical Biomarkers

Current diagnostic markers often detect kidney damage only after significant progression. The lack of sensitive early biomarkers hinders proactive therapy initiation and complicates the establishment of clinical endpoints in trials, slowing drug development.

• High Comorbid Disease Complexity

Patients with DKD typically present with multiple comorbidities, including hypertension, cardiovascular disease, and neuropathy. Managing these interconnected conditions adds clinical complexity and increases risk during treatment, lowering adoption of innovative therapies.

Scope of the Diabetic Kidney Disease Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Diabetic Kidney Disease Companies- Daiichi Sankyo, Prokidney, Astrazeneca, Palatin, Chinook Therapeutics, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.
• Diabetic Kidney Disease Therapies- BAY94-8862, BI 685509, Finerenone (BAY94-8862), Telmisartan capsule 40 mg, PF-00489791, Losartan, Valsartan, MT-3995 and others.
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
• Diabetic Kidney Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Diabetic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Diabetic Kidney Disease Market Access and Reimbursement

Discover more about therapies set to grab major Diabetic Kidney Disease Market Share @ Diabetic Kidney Disease Treatment Market

Table of Contents

1. Key Insights

2. Diabetic Kidney Disease Market Report Introduction

3. Diabetic Kidney Disease Market Overview at a Glance

4. Diabetic Kidney Disease Executive Summary

5. Key Events

6. Diabetic Kidney Disease Market Disease Background and Overview

7. Diabetic Kidney Disease Methodology

8. Diabetic Kidney Disease Population

9. Diabetic Kidney Disease Patient Journey

10. Diabetic Kidney Disease Marketed Drugs

11. Diabetic Kidney Disease Emerging Drugs

12. Diabetic Kidney Disease – 7MM Market Analysis

13. Diabetic Kidney Disease KOL Views

14. Diabetic Kidney Disease Unmet Needs

15. Diabetic Kidney Disease SWOT Analysis

16. Diabetic Kidney Disease Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.